Laboratorio Reig Jofre, S.A. (RJF.MC)
EUR 2.56
(0.0%)
EUR 2.56
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 124.61 Million EUR | 1.36% |
| 2022 | 122.94 Million EUR | -9.91% |
| 2021 | 136.46 Million EUR | 2.86% |
| 2020 | 132.67 Million EUR | -2.07% |
| 2019 | 135.47 Million EUR | 93.72% |
| 2018 | 69.93 Million EUR | 13.2% |
| 2017 | 61.77 Million EUR | -14.6% |
| 2016 | 72.34 Million EUR | 18.83% |
| 2015 | 60.87 Million EUR | -2.71% |
| 2014 | 62.57 Million EUR | 667.85% |
| 2013 | 8.14 Million EUR | -27.92% |
| 2012 | 11.3 Million EUR | -85.65% |
| 2011 | 78.78 Million EUR | -28.2% |
| 2010 | 109.73 Million EUR | 2.95% |
| 2009 | 106.59 Million EUR | -39.28% |
| 2008 | 175.54 Million EUR | -0.62% |
| 2007 | 176.64 Million EUR | 25.06% |
| 2006 | 141.24 Million EUR | 83.07% |
| 2005 | 77.15 Million EUR | 397.89% |
| 2004 | 15.49 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 133.13 Million EUR | 6.83% |
| 2024 Q3 | 130.74 Million EUR | -5.66% |
| 2024 Q2 | 142.88 Million EUR | 7.32% |
| 2023 Q3 | 136.6 Million EUR | -0.92% |
| 2023 Q4 | 124.61 Million EUR | -8.78% |
| 2023 Q1 | -194.55 Million EUR | -258.25% |
| 2023 FY | 124.61 Million EUR | 1.36% |
| 2023 Q2 | 137.88 Million EUR | 170.87% |
| 2022 Q4 | 122.94 Million EUR | -10.66% |
| 2022 FY | 122.94 Million EUR | -9.91% |
| 2022 Q3 | 137.6 Million EUR | -0.09% |
| 2022 Q2 | 137.73 Million EUR | 0.0% |
| 2021 Q2 | 147.49 Million EUR | 7.37% |
| 2021 Q1 | 137.37 Million EUR | 3.54% |
| 2021 FY | 136.46 Million EUR | 2.86% |
| 2021 Q4 | 136.46 Million EUR | -0.68% |
| 2021 Q3 | 137.39 Million EUR | -6.85% |
| 2020 Q2 | 143.96 Million EUR | 1.61% |
| 2020 Q4 | 132.67 Million EUR | -1.95% |
| 2020 Q3 | 135.31 Million EUR | -6.01% |
| 2020 FY | 132.67 Million EUR | -2.07% |
| 2020 Q1 | 141.67 Million EUR | 4.58% |
| 2019 Q2 | 88.65 Million EUR | 2.96% |
| 2019 Q4 | 135.47 Million EUR | 7.24% |
| 2019 FY | 135.47 Million EUR | 93.72% |
| 2019 Q1 | 86.1 Million EUR | 23.12% |
| 2019 Q3 | 126.32 Million EUR | 42.49% |
| 2018 Q3 | 71.82 Million EUR | 5.73% |
| 2018 Q1 | 66.2 Million EUR | 7.16% |
| 2018 FY | 69.93 Million EUR | 13.2% |
| 2018 Q4 | 69.93 Million EUR | -2.64% |
| 2018 Q2 | 67.93 Million EUR | 2.62% |
| 2017 Q1 | 66.07 Million EUR | -8.66% |
| 2017 FY | 61.77 Million EUR | -14.6% |
| 2017 Q2 | 60.36 Million EUR | -8.64% |
| 2017 Q4 | 61.77 Million EUR | 7.91% |
| 2017 Q3 | 57.24 Million EUR | -5.17% |
| 2016 Q4 | 72.34 Million EUR | 15.29% |
| 2016 FY | 72.34 Million EUR | 18.83% |
| 2016 Q1 | 62.3 Million EUR | 2.34% |
| 2016 Q2 | 63.65 Million EUR | 2.17% |
| 2016 Q3 | 62.74 Million EUR | -1.43% |
| 2015 Q4 | 60.87 Million EUR | 9.71% |
| 2015 Q3 | 55.48 Million EUR | -4.99% |
| 2015 FY | 60.87 Million EUR | -2.71% |
| 2015 Q2 | 58.4 Million EUR | -8.78% |
| 2015 Q1 | 64.02 Million EUR | 2.33% |
| 2014 Q2 | 8.23 Million EUR | -22.47% |
| 2014 Q3 | 8.76 Million EUR | 6.54% |
| 2014 FY | 62.57 Million EUR | 667.85% |
| 2014 Q4 | 62.57 Million EUR | 613.56% |
| 2014 Q1 | 10.61 Million EUR | 30.29% |
| 2013 Q2 | 10.91 Million EUR | -15.76% |
| 2013 FY | 8.14 Million EUR | -27.92% |
| 2013 Q4 | 8.14 Million EUR | -28.51% |
| 2013 Q3 | 11.39 Million EUR | 4.44% |
| 2013 Q1 | 12.95 Million EUR | 14.59% |
| 2012 FY | 11.3 Million EUR | -85.65% |
| 2012 Q2 | 72.79 Million EUR | -11.98% |
| 2012 Q3 | 72.31 Million EUR | -0.66% |
| 2012 Q4 | 11.3 Million EUR | -84.36% |
| 2012 Q1 | 82.69 Million EUR | 4.96% |
| 2011 FY | 78.78 Million EUR | -28.2% |
| 2011 Q4 | 78.78 Million EUR | 0.0% |
| 2011 Q2 | 103.8 Million EUR | 0.0% |
| 2010 Q1 | 118.77 Million EUR | 0.0% |
| 2010 FY | 109.73 Million EUR | 2.95% |
| 2010 Q2 | 106.83 Million EUR | -10.05% |
| 2009 FY | 106.59 Million EUR | -39.28% |
| 2008 FY | 175.54 Million EUR | -0.62% |
| 2007 FY | 176.64 Million EUR | 25.06% |
| 2006 FY | 141.24 Million EUR | 83.07% |
| 2005 FY | 77.15 Million EUR | 397.89% |
| 2004 FY | 15.49 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Almirall, S.A. | 911.58 Million EUR | 86.329% |
| Faes Farma, S.A. | 112.68 Million EUR | -10.595% |